CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cognigenics
Company Type: Therapeutics
Main focus: Non-viral delivery of CRISPR-based therapeutics to central nervous system
Company stage: Pre-clinical
Diseases: Neurodegenerative disorders
Genome-editing tool: CRISPR-Cas
Funding stage: Seed stage
Location: Idaho, USA
Website: https://www.cognigenics.io/
Pipeline:
Partners:
Cognigenics is a pre-clinical-stage biotech that has developed a method for intranasal adeno-associated virus (AAV)-based delivery of CRISPR-Cas reagents. Cognigenics’ delivery modality allows the gene-editing cargo to pass the blood brain barrier and reach the central nervous system to treat neurodegenerative disorders.
